CCR8

Summary

CCR8 (C-C motif chemokine receptor 8, HGNC:1609) is a protein-coding gene on chromosome 3p22.1, encoding C-C chemokine receptor type 8 (P51685). G protein-coupled receptor that can bind a variety of chemokines, such as CCL1, CCL8, CCL16, CCL18.

This gene encodes a member of the beta chemokine receptor family, which is predicted to be a seven transmembrane protein similar to G protein-coupled receptors. Chemokines and their receptors are important for the migration of various cell types into the inflammatory sites. This receptor protein preferentially expresses in the thymus. I-309, thymus activation-regulated cytokine (TARC) and macrophage inflammatory protein-1 beta (MIP-1 beta) have been identified as ligands of this receptor. Studies of this receptor and its ligands suggested its role in regulation of monocyte chemotaxis and thymic cell apoptosis. More specifically, this receptor may contribute to the proper positioning of activated T cells within the antigenic challenge sites and specialized areas of lymphoid tissues. This gene is located at the chemokine receptor gene cluster region.

Source: NCBI Gene 1237 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 51 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_005201

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1609
Approved symbol	CCR8
Name	C-C motif chemokine receptor 8
Location	3p22.1
Locus type	gene with protein product
Status	Approved
Aliases	CY6, TER1, CKR-L1, GPR-CY6, CDw198
Ensembl gene	ENSG00000179934
Ensembl biotype	protein_coding
OMIM	601834
Entrez	1237

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000326306, ENST00000414803

RefSeq mRNA: 1 — MANE Select: NM_005201 NM_005201

CCDS: CCDS2684

Canonical transcript exons

ENST00000326306 — 2 exons

Exon	Start	End
ENSE00001288442	39329709	39329829
ENSE00001288452	39332318	39333680

Expression profiles

Bgee: expression breadth broad, 38 present calls, max score 92.66.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.5692 / max 145.6795, expressed in 90 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
36126	0.3647	70
36125	0.1380	47
36127	0.0423	23
36124	0.0240	12

Top tissues by expression

262 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	92.66	gold quality
buccal mucosa cell	CL:0002336	68.21	gold quality
type B pancreatic cell	CL:0000169	67.00	gold quality
diaphragm	UBERON:0001103	63.08	gold quality
granulocyte	CL:0000094	61.26	gold quality
periodontal ligament	UBERON:0008266	60.79	gold quality
vermiform appendix	UBERON:0001154	59.28	gold quality
mucosa of urinary bladder	UBERON:0001259	57.61	gold quality
gall bladder	UBERON:0002110	57.61	gold quality
mucosa of paranasal sinus	UBERON:0005030	56.70	gold quality
caecum	UBERON:0001153	56.46	gold quality
trabecular bone tissue	UBERON:0002483	54.84	gold quality
lymph node	UBERON:0000029	54.61	gold quality
ileal mucosa	UBERON:0000331	54.07	silver quality
skin of hip	UBERON:0001554	53.60	silver quality
thymus	UBERON:0002370	53.26	gold quality
upper leg skin	UBERON:0004262	52.65	silver quality
epithelial cell of pancreas	CL:0000083	52.06	gold quality
blood	UBERON:0000178	50.82	gold quality
frontal pole	UBERON:0002795	50.41	gold quality
middle frontal gyrus	UBERON:0002702	50.30	gold quality
quadriceps femoris	UBERON:0001377	50.27	gold quality
paraflocculus	UBERON:0005351	50.18	gold quality
Brodmann (1909) area 10	UBERON:0013541	50.18	gold quality
pancreatic ductal cell	CL:0002079	50.06	silver quality
vastus lateralis	UBERON:0001379	49.32	gold quality
Brodmann (1909) area 46	UBERON:0006483	49.30	gold quality
blood vessel layer	UBERON:0004797	49.29	gold quality
cerebellar vermis	UBERON:0004720	49.25	gold quality
cervix squamous epithelium	UBERON:0006922	49.20	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-CURD-89	yes	580.64
E-ANND-3	no	2.76

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): STAT6

miRNA regulators (miRDB)

16 targeting CCR8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-3614-5P	99.30	65.25	837
HSA-MIR-196A-3P	99.19	67.34	1204
HSA-MIR-511-5P	98.97	70.94	2268
HSA-MIR-501-5P	98.77	68.88	1328
HSA-MIR-4755-3P	98.77	65.59	1915
HSA-MIR-500A-5P	98.76	69.13	1241
HSA-MIR-1178-3P	98.57	67.09	890
HSA-MIR-4289	98.26	66.90	810
HSA-MIR-124-5P	98.11	67.65	1095
HSA-MIR-1255B-2-3P	97.80	67.04	880
HSA-MIR-4642	97.52	67.60	916

Literature-anchored findings (GeneRIF, showing 35)

• CCR8 mediates rescue from dexamethasone-induced apoptosis via an ERK-dependent pathway (PMID:12525579)
• found in the central nervous system and is associated with phagocytic macrophages (PMID:12547701)
• CCR8 genes and surrounding genomic regions these genes are the result of the duplication of an ancestral gene prior to the divergence of teleost fish. (PMID:12551893)
• Transfected human CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I. (PMID:12645948)
• The induction of CCR8 under conditions associated with vascular smooth muscle cell proliferation and migration raises the possibility that CCR8 may play an important role in vessel wall pathology. (PMID:14576057)
• the axis CCL1-CCR8 links adaptive and innate immune functions that play a role in the initiation and amplification of atopic skin inflammation (PMID:15814739)
• CCR8 ligands are allotropic, binding to distinct sites within CCR8; the human immune system may have evolved to use CCL7 as a selective antagonist of viral chemokine activity at CCR8 but not those of the host ligand (PMID:17023422)
• CCR8 is expressed by a small and heterogeneous population of peripheral blood CD4 memory T cells enriched in T helper type 2 (Th2) effector and T regulatory (Treg) cells. (PMID:17082609)
• CCR8-expressing CD4-positive T lymphocytes are preferentially recruited from the periphery into the lungs of asthmatic individuals, driven by elevated CCL1 levels produced almost exclusively by mast cells and basophils. (PMID:17641040)
• The combination of 17beta-E(2) with the environmental pollutant TCDD is involved in the pathogenesis of endometriosis via up-regulating the chemokine CCR8-I-309. (PMID:17693327)
• There may be a role for CCR8 in the recruitment of T cells to the lung in asthmatics. (PMID:20455898)
• The functional data from human macrophages suggest a potential cross talk between the CCR8 and the Toll-like receptor 4 (TLR4) pathways, both of which are present in chronic obstructive pulmonary disease patients. (PMID:21976223)
• C-terminal clipping of chemokine CCL1/I-309 enhances CCR8-mediated intracellular calcium release and anti-apoptotic activity (PMID:22479563)
• Data show that CCR8 expression by newly activated naive T cells is regulated by skin-specific factor(s) derived primarily from epidermal keratinocytes. (PMID:23043070)
• CCR8(+) myeloid cell subset is expanded in patients with cancer. (PMID:23363815)
• CCL1-CCR8 interaction may play a critical role in lymphocytic recruitment in IgG4-related sclerosing cholangitis and type 1 autoimmune pancreatitis, leading to duct-centred inflammation and obliterative phlebitis. (PMID:23811304)
• Identification of human CCR8 as a CCL18 receptor. (PMID:23999500)
• findings suggest that CCR8 expression in ALCL is more closely related to the presence of DUSP22 rearrangements than to cutaneous involvement and that the function of CCR8 may extend beyond its skin-homing properties in this disease (PMID:25390351)
• Epidermal-derived vitamin D3 metabolites and prostaglandins provide an essential cue for the localization of CCR8+ immune surveillance T cells within healthy human skin. (PMID:26002980)
• High CCR8 expression is associated with high recurrence in kidney cancer. (PMID:26716905)
• Role of Conserved Disulfide Bridges and Aromatic Residues in Extracellular Loop 2 of Chemokine Receptor CCR8 for Chemokine and Small Molecule Binding. (PMID:27226537)
• Authors demonstrate the pivotal role of CCR8(+) Treg cells in restraining immunity and highlight the potential clinical implications of this discovery. (PMID:28533380)
• Long-lived memory T cells in human skin can be defined by the expression of CCR8. (PMID:29427415)
• Blocking CCR8 via a small molecule inhibitor or short hairpin (sh)RNA mitigated the decrease in Ecadherin, and increase in MMP2 and VEGFC, caused by human recombinant (r)CCL18. CCR8 knockdown by shRNA reversed rCCL18induced cancer cell invasion, migration and epithelialmesenchymal transition (PMID:30592282)
• ARNT-dependent CCR8 reprogrammed LDH isoform expression correlates with poor clinical outcomes of prostate cancer. (PMID:32319143)
• Clinical and prognostic significance of CC chemokine receptor type 8 protein expression in gastrointestinal stromal tumors. (PMID:32884223)
• Chemokine (C-C Motif) Ligand 1 Derived from Tumor-Associated Macrophages Contributes to Esophageal Squamous Cell Carcinoma Progression via CCR8-Mediated Akt/Proline-Rich Akt Substrate of 40 kDa/Mammalian Target of Rapamycin Pathway. (PMID:33460563)
• Immunomodulation of T Helper Cells by Tumor Microenvironment in Oral Cancer Is Associated With CCR8 Expression and Rapid Membrane Vitamin D Signaling Pathway. (PMID:34025655)
• Chemokine CCL18 Promotes Phagocytosis Through Its Receptor CCR8 Rather than PITPNM3 in Human Microglial Cells. (PMID:35041514)
• CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. (PMID:35140181)
• Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. (PMID:36352891)
• Development of a cellular model to study CCR8 signaling in tumor-infiltrating regulatory T cells. (PMID:38231448)
• Unveiling the structural mechanisms of nonpeptide ligand recognition and activation in human chemokine receptor CCR8. (PMID:38306437)
• Cryo-EM Structure and Biochemical Analysis of the Human Chemokine Receptor CCR8. (PMID:38985857)
• The chemokine receptor CCR8 is not a high-affinity receptor for the human chemokine CCL18. (PMID:39259753)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccr11.1	ENSDARG00000070755
danio_rerio	ccr2	ENSDARG00000079829
danio_rerio	cabz01093075.1	ENSDARG00000086616
danio_rerio	ccr8.1	ENSDARG00000095789
danio_rerio	si:ch211-207g17.3	ENSDARG00000105363
danio_rerio	si:cabz01093077.1	ENSDARG00000105467
mus_musculus	Ccr8	ENSMUSG00000042262
rattus_norvegicus	Ccr8	ENSRNOG00000026759

Paralogs (23): CCR6 (ENSG00000112486), CCRL2 (ENSG00000121797), CCR2 (ENSG00000121807), CXCR4 (ENSG00000121966), CCR7 (ENSG00000126353), ACKR4 (ENSG00000129048), ACKR3 (ENSG00000144476), ACKR2 (ENSG00000144648), RGR (ENSG00000148604), CXCR5 (ENSG00000160683), CCR5 (ENSG00000160791), CXCR1 (ENSG00000163464), CCR1 (ENSG00000163823), CX3CR1 (ENSG00000168329), CXCR6 (ENSG00000172215), XCR1 (ENSG00000173578), CCR9 (ENSG00000173585), CXCR2 (ENSG00000180871), GALR2 (ENSG00000182687), CCR3 (ENSG00000183625), CCR4 (ENSG00000183813), CCR10 (ENSG00000184451), CXCR3 (ENSG00000186810)

Protein

Protein identifiers

C-C chemokine receptor type 8 — P51685 (reviewed: P51685)

Alternative names: CC chemokine receptor CHEMR1, CMKBRL2, Chemokine receptor-like 1, GPR-CY6, TER1

All UniProt accessions (2): P51685, C9JIP9

UniProt curated annotations — full annotation on UniProt →

Function. G protein-coupled receptor that can bind a variety of chemokines, such as CCL1, CCL8, CCL16, CCL18. Regulates monocyte and eosinophil chemotaxis. Undergoes internalization upon CCL18 binding, leading to induced migration and calcium flux of highly polarized Th2 cells. In microglial cells, promotes phagocytosis with CCL18 through NF-kappa-B and Src signaling pathways. Stimulation of the CCL1-CCR8 signaling axis protects the gut from acute intestinal damage. (Microbial infection) Acts as a coreceptor for HIV-1 and HIV-2 viruses. (Microbial infection) Acts as a receptor for Kaposi virus protein vCCL1/K6 and thereby inhibits apoptosis in the targeted cells.

Subunit / interactions. Interacts with GNAI1. (Microbial infection) Interacts with Kaposi virus proteins vCCL1 and vCCL2.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in unstimulated CD4(+) and CD8(+) T-cells and polymorphonuclear cells.

Similarity. Belongs to the G-protein coupled receptor 1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
P51685-1	1	yes
P51685-2	2

RefSeq proteins (1): NP_005192* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR000355	Chemokine_rcpt	Family
IPR004068	Chemokine_CCR8	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain
IPR050119	CCR1-9-like	Family

Pfam: PF00001

UniProt features (38 total): helix 9, topological domain 8, transmembrane region 7, mutagenesis site 3, strand 3, turn 3, disulfide bond 2, chain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
8XML	ELECTRON MICROSCOPY	2.58
8TLM	ELECTRON MICROSCOPY	2.9
8KFX	ELECTRON MICROSCOPY	2.96
8KFY	ELECTRON MICROSCOPY	3.06
8U1U	ELECTRON MICROSCOPY	3.1
8KFZ	ELECTRON MICROSCOPY	3.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P51685-F1	82.21	0.57

Antibody-complex structures (SAbDab): 6 — 8KFX, 8KFY, 8KFZ, 8TLM, 8U1U, 8XML

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 25–272, 106–183

Mutagenesis-validated functional residues (3):

Position	Phenotype
113	strong decrease in ability to mediate calcium mobilization.
172	strong decrease in ability to mediate calcium mobilization.
286	strong decrease in ability to mediate calcium mobilization.

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-380108	Chemokine receptors bind chemokines
R-HSA-418594	G alpha (i) signalling events
R-HSA-162582	Signal Transduction
R-HSA-372790	Signaling by GPCR
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)
R-HSA-375276	Peptide ligand-binding receptors
R-HSA-388396	GPCR downstream signalling
R-HSA-500792	GPCR ligand binding

MSigDB gene sets: 122 (showing top): GOBP_CELL_CHEMOTAXIS, GOBP_RESPONSE_TO_PEPTIDE, MODULE_64, GOCC_CELL_SURFACE, GOBP_TAXIS, REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS, MODULE_289, chr3p22, GAVIN_FOXP3_TARGETS_CLUSTER_P3, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, GOCC_SIDE_OF_MEMBRANE, BOCHKIS_FOXA2_TARGETS, GOMF_CYTOKINE_BINDING, REACTOME_CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS, GOMF_TRANSMEMBRANE_SIGNALING_RECEPTOR_ACTIVITY

GO Biological Process (11): chemotaxis (GO:0006935), immune response (GO:0006955), cell adhesion (GO:0007155), G protein-coupled receptor signaling pathway (GO:0007186), positive regulation of cytosolic calcium ion concentration (GO:0007204), calcium-mediated signaling (GO:0019722), cell chemotaxis (GO:0060326), signal transduction (GO:0007165), cell surface receptor signaling pathway (GO:0007166), chemokine-mediated signaling pathway (GO:0070098), cellular response to cytokine stimulus (GO:0071345)

GO Molecular Function (5): G protein-coupled receptor activity (GO:0004930), chemokine receptor activity (GO:0004950), coreceptor activity (GO:0015026), C-C chemokine receptor activity (GO:0016493), C-C chemokine binding (GO:0019957)

GO Cellular Component (3): plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Signaling by GPCR	2
Peptide ligand-binding receptors	1
GPCR downstream signalling	1
Signal Transduction	1
GPCR ligand binding	1
Class A/1 (Rhodopsin-like receptors)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular process	2
signal transduction	2
G protein-coupled receptor signaling pathway	2
chemokine binding	2
response to chemical	1
taxis	1
immune system process	1
response to stimulus	1
G protein-coupled receptor activity	1
regulation of biological quality	1
intracellular signaling cassette	1
chemotaxis	1
cell migration	1
cellular response to chemical stimulus	1
cell communication	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
cytokine-mediated signaling pathway	1
cellular response to chemokine	1
response to cytokine	1
transmembrane signaling receptor activity	1
G protein-coupled chemoattractant receptor activity	1
cytokine receptor activity	1
chemokine-mediated signaling pathway	1
signaling receptor activity	1
chemokine receptor activity	1
C-C chemokine binding	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1230 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCR8	CCL1	P22362	997
CCR8	CCL17	Q92583	992
CCR8	CCL18	P55774	992
CCR8	CCL22	O00626	988
CCR8	CCL4	P13236	951
CCR8	CCL8	P78388	939
CCR8	CCL16	O15467	916
CCR8	TERT	O14746	880
CCR8	CCL20	P78556	856
CCR8	CCR2	P41597	828
CCR8	CCR3	P51677	821
CCR8	CCL5	P13501	809
CCR8	CCRL2	O00421	795
CCR8	CCL19	Q99731	791
CCR8	CCL2	P13500	783

IntAct

22 interactions, top by confidence:

A	B	Type	Score
CCR8	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
RAMP1	CCR8	psi-mi:“MI:0915”(physical association)	0.400
CCR8	RAMP2	psi-mi:“MI:0915”(physical association)	0.400
RAMP3	CCR8	psi-mi:“MI:0915”(physical association)	0.400
RAMP2	CCR8	psi-mi:“MI:0915”(physical association)	0.400
CCR8	RAMP3	psi-mi:“MI:0915”(physical association)	0.400
SPP1	CCR8	psi-mi:“MI:0915”(physical association)	0.370
SPNS1	CCR8	psi-mi:“MI:0915”(physical association)	0.370
RTN3	CCR8	psi-mi:“MI:0915”(physical association)	0.370
PAQR6	CCR8	psi-mi:“MI:0915”(physical association)	0.370
NAGPA	CCR8	psi-mi:“MI:0915”(physical association)	0.370
THY1	CCR8	psi-mi:“MI:0915”(physical association)	0.370
ATP2A1	CCR8	psi-mi:“MI:0915”(physical association)	0.370
ERGIC3	CCR8	psi-mi:“MI:0915”(physical association)	0.370
GABRD	CCR8	psi-mi:“MI:0915”(physical association)	0.370
PLEKHB1	CCR8	psi-mi:“MI:0915”(physical association)	0.370
UCKL1	CCR8	psi-mi:“MI:0915”(physical association)	0.370
EI24	CCR8	psi-mi:“MI:0915”(physical association)	0.370
GABBR1	CCR8	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (14): SPP1 (Two-hybrid), SPNS1 (Two-hybrid), RTN3 (Two-hybrid), PAQR6 (Two-hybrid), NAGPA (Two-hybrid), THY1 (Two-hybrid), ATP2A1 (Two-hybrid), ERGIC3 (Two-hybrid), GABRD (Two-hybrid), PLEKHB1 (Two-hybrid), UCKL1 (Two-hybrid), EI24 (Two-hybrid), GABBR1 (Two-hybrid), CCR8 (Affinity Capture-MS)

ESM2 similar proteins: A0A4W3GG95, B0F9W3, B3G515, E7FEL0, F7EQ49, O00398, O08878, O46685, O70526, O97665, P25023, P25105, P30411, P32299, P46093, P47774, P49684, P50132, P51679, P51680, P51685, P51686, P55085, P55086, P56484, P79960, Q15743, Q1JQB3, Q1WLP9, Q28642, Q2HJA4, Q2TAD5, Q4KLH9, Q4VA82, Q63645, Q80Z39, Q8BFQ3, Q8BFU7, Q8BLG2, Q8BMP4

Diamond homologs: A0A287A2K5, C8YUV0, O00155, O02836, O08786, O15973, O18935, O19012, O19014, O19025, O19032, O19054, O19091, O62729, O77408, O77700, O77721, O77830, O97665, O97772, P04761, P08482, P0C5I1, P11229, P12657, P17200, P18089, P19328, P22270, P25021, P30545, P30551, P30552, P30553, P30796, P32211, P32238, P32239, P32302, P46627

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
CCL1	up-regulates	CCR8	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

51 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	43
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

470 predictions. Top by Δscore:

Variant	Effect	Δscore
3:39329830:G:GG	donor_gain	1.0000
3:39329830:GTAT:G	donor_loss	1.0000
3:39332316:A:AC	acceptor_loss	1.0000
3:39329828:AG:A	donor_gain	0.9900
3:39329829:GG:G	donor_gain	0.9900
3:39332309:T:TA	acceptor_gain	0.9900
3:39332311:T:TA	acceptor_gain	0.9900
3:39332316:A:AG	acceptor_gain	0.9900
3:39332317:G:GG	acceptor_gain	0.9900
3:39332603:A:AG	acceptor_gain	0.9900
3:39332604:G:GG	acceptor_gain	0.9900
3:39329825:CTAAG:C	donor_gain	0.9800
3:39332317:GGT:G	acceptor_gain	0.9800
3:39332317:GGTC:G	acceptor_gain	0.9700
3:39332604:GACCT:G	acceptor_gain	0.9700
3:39329826:TAAG:T	donor_gain	0.9600
3:39329827:AAG:A	donor_gain	0.9600
3:39330787:G:GG	donor_gain	0.9500
3:39332301:T:G	acceptor_gain	0.9500
3:39332317:GGTCC:G	acceptor_gain	0.9500
3:39332599:TTTCA:T	acceptor_loss	0.9500
3:39332600:TTCAG:T	acceptor_loss	0.9500
3:39332601:TCAGA:T	acceptor_loss	0.9500
3:39332602:CAGA:C	acceptor_loss	0.9500
3:39332603:AGAC:A	acceptor_loss	0.9500
3:39332604:G:T	acceptor_loss	0.9500
3:39332316:AG:A	acceptor_gain	0.9300
3:39332317:GG:G	acceptor_gain	0.9300
3:39332604:GAC:G	acceptor_gain	0.9300
3:39332303:T:TA	acceptor_gain	0.9100

AlphaMissense

2356 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:39332713:A:C	S128R	0.996
3:39332715:T:A	S128R	0.996
3:39332715:T:G	S128R	0.996
3:39332628:G:C	W99C	0.995
3:39332628:G:T	W99C	0.995
3:39332803:T:A	W158R	0.993
3:39332803:T:C	W158R	0.993
3:39332626:T:A	W99R	0.992
3:39332626:T:C	W99R	0.992
3:39333250:T:C	F307L	0.991
3:39333252:C:A	F307L	0.991
3:39333252:C:G	F307L	0.991
3:39332647:T:A	C106S	0.990
3:39332648:G:C	C106S	0.990
3:39332686:A:C	S119R	0.990
3:39332688:C:A	S119R	0.990
3:39332688:C:G	S119R	0.990
3:39332878:T:A	C183S	0.990
3:39332879:G:C	C183S	0.990
3:39332476:A:C	S49R	0.988
3:39332478:T:A	S49R	0.988
3:39332478:T:G	S49R	0.988
3:39332878:T:C	C183R	0.985
3:39333089:C:G	P253R	0.985
3:39332647:T:C	C106R	0.983
3:39332880:T:G	C183W	0.983
3:39332490:C:A	N53K	0.981
3:39332490:C:G	N53K	0.981
3:39332648:G:A	C106Y	0.981
3:39332649:C:G	C106W	0.981

dbSNP variants (sampled 300 via entrez): RS1000796519 (3:39330857 T>A,C), RS1000878714 (3:39332009 C>T), RS1001187760 (3:39330410 G>A,T), RS1002149306 (3:39330236 G>C), RS1002246639 (3:39330531 A>G), RS1002875454 (3:39332464 C>T), RS1003519559 (3:39328910 C>T), RS1004226735 (3:39328679 A>G), RS1004363206 (3:39332671 T>C), RS1004665543 (3:39332310 G>A,C), RS1006034691 (3:39331237 G>T), RS1006338914 (3:39330753 C>A,T), RS1007109339 (3:39328047 G>T), RS1007258564 (3:39331660 G>A), RS1007330680 (3:39331396 C>T)

Disease associations

OMIM: gene MIM:601834 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003518_42	Daytime sleep phenotypes	8.000000e-06
GCST007932_44	Medication use (thyroid preparations)	4.000000e-11

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007828	daytime rest measurement
EFO:0009933	Thyroid preparation use measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4596 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 748 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL2205807	ABAMETAPIR	4	748

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Chemokine receptors

Most potent curated ligand interactions (7 total), top 7:

Ligand	Action	Affinity	Parameter
vMIP-I	Full agonist	9.9	pIC50
CCL1	Full agonist	9.8	pIC50
[125I]CCL1 (human)	Full agonist	9.7	pKd
vMCC-I	Antagonist	9.41	pIC50
[125I]CCL1 (mouse)	Full agonist	8.7	pKd
vMIP-II	Antagonist	8.1	pIC50
ZK 756326	Full agonist	5.7	pIC50

ChEMBL bioactivities

248 potent at pChembl≥5 of 256 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.77	Ki	0.17	nM	CHEMBL218374
9.52	Ki	0.3	nM	CHEMBL374939
9.52	IC50	0.3	nM	CHEMBL374939
9.15	Ki	0.7	nM	CHEMBL386308
9.15	Ki	0.7	nM	CHEMBL221865
9.00	IC50	1	nM	CHEMBL205993
9.00	Ki	1	nM	CHEMBL386308
9.00	IC50	1	nM	CHEMBL5424187
8.96	Ki	1.1	nM	CHEMBL373739
8.92	IC50	1.2	nM	CHEMBL5404620
8.89	IC50	1.3	nM	CHEMBL5397693
8.82	Ki	1.5	nM	CHEMBL375854
8.80	Ki	1.6	nM	CHEMBL218375
8.80	Ki	1.6	nM	CHEMBL221867
8.80	Ki	1.6	nM	CHEMBL376910
8.77	IC50	1.7	nM	CHEMBL5411391
8.77	IC50	1.7	nM	CHEMBL5412884
8.66	Ki	2.2	nM	CHEMBL220701
8.64	Ki	2.3	nM	CHEMBL218037
8.62	IC50	2.399	nM	CHEMBL567417
8.60	Ki	2.5	nM	CHEMBL220753
8.58	IC50	2.63	nM	CHEMBL568523
8.58	IC50	2.63	nM	CHEMBL579072
8.55	IC50	2.818	nM	CHEMBL568294
8.46	Ki	3.5	nM	CHEMBL221130
8.40	IC50	4	nM	CHEMBL380492
8.40	IC50	4	nM	CHEMBL5399936
8.40	IC50	4	nM	CHEMBL221251
8.39	Ki	4.1	nM	CHEMBL221904
8.38	Ki	4.2	nM	CHEMBL221251
8.38	Ki	4.2	nM	CHEMBL385108
8.38	IC50	4.2	nM	CHEMBL374527
8.36	Ki	4.4	nM	CHEMBL218503
8.31	IC50	4.898	nM	CHEMBL574655
8.29	IC50	5.1	nM	CHEMBL221790
8.28	Ki	5.21	nM	CHEMBL375315
8.27	Ki	5.4	nM	CHEMBL218036
8.25	IC50	5.623	nM	CHEMBL568522
8.22	Ki	6	nM	CHEMBL205993
8.22	IC50	6	nM	CHEMBL5404280
8.22	IC50	6	nM	CHEMBL5412094
8.21	IC50	6.1	nM	CHEMBL221586
8.20	Ki	6.3	nM	CHEMBL218218
8.18	IC50	6.607	nM	CHEMBL584087
8.17	Ki	6.7	nM	CHEMBL221977
8.16	IC50	6.9	nM	CHEMBL218297
8.14	Ki	7.2	nM	CHEMBL374979
8.12	IC50	7.65	nM	CHEMBL220652
8.09	IC50	8.128	nM	CHEMBL566543
8.07	IC50	8.44	nM	CHEMBL5407071

PubChem BioAssay actives

248 with measured affinity, of 394 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
ethyl 4-[(4-benzamidonaphthalen-1-yl)sulfonylamino]piperidine-1-carboxylate	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0002	uM
N-[4-[(1-butanoylpiperidin-4-yl)sulfamoyl]naphthalen-1-yl]-2-methylbenzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0003	uM
2-methyl-N-[4-[[1-[(2S)-pyrrolidine-2-carbonyl]piperidin-4-yl]sulfamoyl]naphthalen-1-yl]benzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0007	uM
N-methyl-4-[[4-[(2-methylbenzoyl)amino]naphthalen-1-yl]sulfonylamino]piperidine-1-carboxamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0007	uM
2-[3-[[1-[[3-(2-chlorophenoxy)phenyl]methyl]piperidin-4-yl]carbamoyl]-3-phenylpyrrolidin-1-yl]-2-methylpropanoic acid	264168: Inhibition of I309-induced chemotaxis in L1.2 cells expressing CCR8	ic50	0.0010	uM
N-[2-chloro-6-methyl-4-[[(1R)-1-(1-methylpiperidin-4-yl)ethyl]sulfamoyl]phenyl]-2-methylbenzamide	2029995: Antagonist activity against CCR8 (unknown origin) expressed in CHO-K1 cells preincubated for 1 hr followed by CCL1 addition measured after 24 hrs by ONE-Glo assay	ic50	0.0010	uM
2-methyl-N-[4-[[1-(pyrrolidine-1-carbonyl)piperidin-4-yl]sulfamoyl]naphthalen-1-yl]benzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0011	uM
2-methyl-N-[4-[[(1R)-1-(1-methylpiperidin-4-yl)ethyl]sulfamoyl]naphthalen-1-yl]benzamide	2029995: Antagonist activity against CCR8 (unknown origin) expressed in CHO-K1 cells preincubated for 1 hr followed by CCL1 addition measured after 24 hrs by ONE-Glo assay	ic50	0.0012	uM
3-chloro-2-methyl-N-[2-methyl-4-[[(1R)-1-(1-methylpiperidin-4-yl)ethyl]sulfamoyl]phenyl]benzamide	2029995: Antagonist activity against CCR8 (unknown origin) expressed in CHO-K1 cells preincubated for 1 hr followed by CCL1 addition measured after 24 hrs by ONE-Glo assay	ic50	0.0013	uM
N-[4-[[1-(azetidine-3-carbonyl)piperidin-4-yl]sulfamoyl]naphthalen-1-yl]-2-methylbenzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0015	uM
ethyl 4-[[4-[(2-methylbenzoyl)amino]naphthalen-1-yl]sulfonylamino]piperidine-1-carboxylate	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0016	uM
N,N-dimethyl-4-[[4-[(2-methylbenzoyl)amino]naphthalen-1-yl]sulfonylamino]piperidine-1-carboxamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0016	uM
N-[4-[[1-(4-aminobutanoyl)piperidin-4-yl]sulfamoyl]naphthalen-1-yl]-2-methylbenzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0016	uM
4-chloro-2-methyl-N-[2-methyl-4-[[(1R)-1-(1-methylpiperidin-4-yl)ethyl]sulfamoyl]phenyl]benzamide	2029995: Antagonist activity against CCR8 (unknown origin) expressed in CHO-K1 cells preincubated for 1 hr followed by CCL1 addition measured after 24 hrs by ONE-Glo assay	ic50	0.0017	uM
5-chloro-2-methyl-N-[2-methyl-4-[[(1R)-1-(1-methylpiperidin-4-yl)ethyl]sulfamoyl]phenyl]benzamide	2029995: Antagonist activity against CCR8 (unknown origin) expressed in CHO-K1 cells preincubated for 1 hr followed by CCL1 addition measured after 24 hrs by ONE-Glo assay	ic50	0.0017	uM
N-ethyl-4-[[4-[(2-methylbenzoyl)amino]naphthalen-1-yl]sulfonylamino]piperidine-1-carboxamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0022	uM
ethyl 4-[(5-benzamidonaphthalen-1-yl)sulfonylamino]piperidine-1-carboxylate	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0023	uM
(5-amino-2-pyridinyl)-[9-[(2-ethyl-2-propyl-3H-1-benzofuran-4-yl)methyl]-3,9-diazaspiro[5.5]undecan-3-yl]methanone	442859: Antagonist activity at human CCR8	ic50	0.0024	uM
2-methyl-N-[4-[(1-propanoylpiperidin-4-yl)sulfamoyl]naphthalen-1-yl]benzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0025	uM
(5-amino-2-pyridinyl)-[9-[(2,2-dimethyl-3H-1-benzofuran-7-yl)methyl]-3,9-diazaspiro[5.5]undecan-3-yl]methanone	442859: Antagonist activity at human CCR8	ic50	0.0026	uM
(5-amino-2-pyridinyl)-[9-[(3,3-difluoro-2,2-dimethyl-1-benzofuran-7-yl)methyl]-3,9-diazaspiro[5.5]undecan-3-yl]methanone	442859: Antagonist activity at human CCR8	ic50	0.0026	uM
(5-amino-2-pyridinyl)-[9-[(2-tert-butyl-2-methyl-3H-1-benzofuran-4-yl)methyl]-3,9-diazaspiro[5.5]undecan-3-yl]methanone	442859: Antagonist activity at human CCR8	ic50	0.0028	uM
N-[4-[[1-(azetidine-1-carbonyl)piperidin-4-yl]sulfamoyl]naphthalen-1-yl]-2-methylbenzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0035	uM
2-[4-[[1-[[3-(2-chlorophenoxy)phenyl]methyl]piperidin-4-yl]carbamoyl]-4-phenylpiperidin-1-yl]-2-methylpropanoic acid	264168: Inhibition of I309-induced chemotaxis in L1.2 cells expressing CCR8	ic50	0.0040	uM
2-methyl-N-[4-[[1-(4-methylpiperazine-1-carbonyl)piperidin-4-yl]sulfamoyl]naphthalen-1-yl]benzamide	2029995: Antagonist activity against CCR8 (unknown origin) expressed in CHO-K1 cells preincubated for 1 hr followed by CCL1 addition measured after 24 hrs by ONE-Glo assay	ic50	0.0040	uM
N-[2,5-dimethyl-4-[[(1R)-1-(1-methylpiperidin-4-yl)ethyl]sulfamoyl]phenyl]-2-methylbenzamide	2029995: Antagonist activity against CCR8 (unknown origin) expressed in CHO-K1 cells preincubated for 1 hr followed by CCL1 addition measured after 24 hrs by ONE-Glo assay	ic50	0.0040	uM
N-[4-[[1-(2-aminoacetyl)piperidin-4-yl]sulfamoyl]naphthalen-1-yl]-2-methylbenzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0041	uM
3-pyrrolidin-1-ylpropyl 4-[[4-[(2-methylbenzoyl)amino]naphthalen-1-yl]sulfonylamino]piperidine-1-carboxylate	277748: Antagonist activity against human CCR8 expressed in CHO/Galpha16 cells assessed as inhibition of CCL1-induced increase of intracellular calcium by FLIPR assay	ic50	0.0042	uM
2-methyl-N-[4-[[1-(piperidine-1-carbonyl)piperidin-4-yl]sulfamoyl]naphthalen-1-yl]benzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0042	uM
N-[4-(cyclohexylsulfamoyl)naphthalen-1-yl]benzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0044	uM
[9-[[3-(2-methoxyphenoxy)phenyl]methyl]-3,9-diazaspiro[5.5]undecan-3-yl]-pyrimidin-4-ylmethanone	442859: Antagonist activity at human CCR8	ic50	0.0049	uM
N-[4-[(1-butanoylpiperidin-4-yl)sulfamoyl]naphthalen-1-yl]-3-methylbenzamide	277748: Antagonist activity against human CCR8 expressed in CHO/Galpha16 cells assessed as inhibition of CCL1-induced increase of intracellular calcium by FLIPR assay	ic50	0.0051	uM
ethyl 4-[[4-[(2-methylphenyl)carbamoyl]naphthalen-1-yl]sulfonylamino]piperidine-1-carboxylate	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0052	uM
N-[4-[[1-(2-hydroxyacetyl)piperidin-4-yl]sulfamoyl]naphthalen-1-yl]-2-methylbenzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0054	uM
(2-amino-4-pyridinyl)-[9-[(2,2-dimethylchromen-8-yl)methyl]-3,9-diazaspiro[5.5]undecan-3-yl]methanone	442859: Antagonist activity at human CCR8	ic50	0.0056	uM
N-[5-chloro-2-methyl-4-[[(1R)-1-(1-methylpiperidin-4-yl)ethyl]sulfamoyl]phenyl]-2-methylbenzamide	2029995: Antagonist activity against CCR8 (unknown origin) expressed in CHO-K1 cells preincubated for 1 hr followed by CCL1 addition measured after 24 hrs by ONE-Glo assay	ic50	0.0060	uM
N-[5-fluoro-2-methyl-4-[[(1R)-1-(1-methylpiperidin-4-yl)ethyl]sulfamoyl]phenyl]-2-methylbenzamide	2029995: Antagonist activity against CCR8 (unknown origin) expressed in CHO-K1 cells preincubated for 1 hr followed by CCL1 addition measured after 24 hrs by ONE-Glo assay	ic50	0.0060	uM
N-[4-[(1-butanoylpiperidin-4-yl)sulfamoyl]naphthalen-1-yl]cyclohexanecarboxamide	277748: Antagonist activity against human CCR8 expressed in CHO/Galpha16 cells assessed as inhibition of CCL1-induced increase of intracellular calcium by FLIPR assay	ic50	0.0061	uM
2-methyl-N-[4-[[1-(morpholine-4-carbonyl)piperidin-4-yl]sulfamoyl]naphthalen-1-yl]benzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0063	uM
(2-amino-4-pyridinyl)-[9-[(2,2-dimethyl-1,3-benzodioxol-4-yl)methyl]-3,9-diazaspiro[5.5]undecan-3-yl]methanone	442859: Antagonist activity at human CCR8	ic50	0.0066	uM
N-[4-[(1-acetylpiperidin-4-yl)sulfamoyl]naphthalen-1-yl]-2-methylbenzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0067	uM
N-[4-[(1-butanoylpiperidin-4-yl)sulfamoyl]naphthalen-1-yl]-4-tert-butylbenzamide	277748: Antagonist activity against human CCR8 expressed in CHO/Galpha16 cells assessed as inhibition of CCL1-induced increase of intracellular calcium by FLIPR assay	ic50	0.0069	uM
N-[4-[[1-(cyclopropanecarbonyl)piperidin-4-yl]sulfamoyl]naphthalen-1-yl]-2-methylbenzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0072	uM
N-[4-[(1-butanoylpiperidin-4-yl)sulfamoyl]naphthalen-1-yl]-2-phenylbutanamide	277748: Antagonist activity against human CCR8 expressed in CHO/Galpha16 cells assessed as inhibition of CCL1-induced increase of intracellular calcium by FLIPR assay	ic50	0.0076	uM
(5-amino-2-pyridinyl)-[9-[(2,2-dimethyl-3H-1-benzofuran-4-yl)methyl]-3,9-diazaspiro[5.5]undecan-3-yl]methanone	442859: Antagonist activity at human CCR8	ic50	0.0081	uM
2-methyl-N-[2-methyl-4-[[(1R)-1-(1-methylpiperidin-4-yl)ethyl]sulfamoyl]phenyl]benzamide	2030002: Inhibition of CCR8 (unknown origin)-mediated beta-arrestin downstream signalling in CCL1-induced CHO cells assessed as beta-lactamase level by Tango assay	ic50	0.0084	uM
N-[4-[[1-(cyclopentanecarbonyl)piperidin-4-yl]sulfamoyl]naphthalen-1-yl]-2-methylbenzamide	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0091	uM
ethyl 4-[[4-(cyclohexylcarbamoyl)naphthalen-1-yl]sulfonylamino]piperidine-1-carboxylate	277746: Binding affinity to human CCR8 expressed in L1.2 cells by FMAT assay	ki	0.0095	uM
N-[4-[(1-butanoylpiperidin-4-yl)sulfamoyl]naphthalen-1-yl]-4-methylbenzamide	277748: Antagonist activity against human CCR8 expressed in CHO/Galpha16 cells assessed as inhibition of CCL1-induced increase of intracellular calcium by FLIPR assay	ic50	0.0095	uM
3-(dimethylamino)propyl 4-[[4-[(2-methylbenzoyl)amino]naphthalen-1-yl]sulfonylamino]piperidine-1-carboxylate	277748: Antagonist activity against human CCR8 expressed in CHO/Galpha16 cells assessed as inhibition of CCL1-induced increase of intracellular calcium by FLIPR assay	ic50	0.0098	uM

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
nickel sulfate	affects expression, increases expression	2
fluorene-9-bisphenol	increases expression	1
terbufos	increases methylation	1
hydroxyhydroquinone	decreases expression	1
zinc chloride	decreases expression	1
ferrous sulfate	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
1-nitropyrene	decreases expression	1
CGP 52608	affects binding, increases reaction	1
Arsenic Trioxide	decreases expression	1
Arsenic	affects expression	1
Benzo(a)pyrene	increases methylation	1
Calcium	affects abundance	1
Cyclophosphamide	decreases expression	1
Fonofos	increases methylation	1
Methapyrilene	increases methylation	1
Parathion	increases methylation	1
Silicon Dioxide	decreases expression	1
Cyclosporine	increases methylation	1
Aflatoxin B1	decreases methylation	1
Antirheumatic Agents	decreases expression	1
Soot	decreases expression	1

ChEMBL screening assays

41 unique, capped per target: 23 binding, 18 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1045844	Functional	Antagonist activity at human CCR8	Increasing selectivity of CC chemokine receptor 8 antagonists by engineering nondesolvation related interactions with the intended and off-target binding sites. — J Med Chem
CHEMBL2039639	Binding	Inhibition of human CCR8 by FLIPR analysis	The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity. — Bioorg Med Chem Lett

Cellosaurus cell lines

10 cell lines: 5 cancer cell line, 3 spontaneously immortalized cell line, 2 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1R22	NP-2/CCR8	Cancer cell line	Male
CVCL_1R28	NP-2/CD4/CCR8	Cancer cell line	Male
CVCL_C8V8	4DE4-CCR8	Cancer cell line
CVCL_E6A2	CHO-CCR8	Spontaneously immortalized cell line	Female
CVCL_E6AC	HEK293-CCR8	Transformed cell line	Female
CVCL_E6P6	Genomeditech CHO-K1 H_CCR8	Spontaneously immortalized cell line	Female
CVCL_E6TD	Genomeditech HEK-293 H_CCR8	Transformed cell line	Female
CVCL_E6VP	Genomeditech Jurkat H_CCR8	Cancer cell line	Male
CVCL_KW62	PathHunter CHO-K1 CCR8 beta-arrestin	Spontaneously immortalized cell line	Female
CVCL_S494	GHOST(3).CCR8	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.